Voyager Therapeutics (VYGR) Other Accumulated Expenses (2014 - 2026)

Voyager Therapeutics has reported Other Accumulated Expenses for 13 years, with the latest figure at $511000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $511000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $511000.0 (changed N/A YoY) and the FY2025 annual result came in at $549000.0, down 54.29% from the prior year.
• Other Accumulated Expenses fell to $511000.0 in Q1 2026 per VYGR's latest filing, from $549000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $7.0 million in Q3 2024 and troughed at $511000.0 in Q1 2026.
• A 5-year average of $3.4 million and a median of $3.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 124.69% in 2024, down 62.47% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $2.8 million in 2022, then increased by 12.99% to $3.2 million in 2023, then slumped by 62.47% to $1.2 million in 2024, then sank by 54.29% to $549000.0 in 2025, then declined by 6.92% to $511000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $511000.0, $549000.0, and $1.2 million for Q1 2026, Q4 2025, and Q4 2024 respectively.